Retrophin Names ViiV Executive as Its New President and CEO

Rare Daily Staff

Rare disease drug developer Retrophin said it appointed Eric Dube as president and CEO, effective January 4, replacing Stephen Aselage, who last year announced his plans to retire.

Dube joins Retrophin from ViiV Healthcare, where he served as president of North America for the GlaxoSmithKline subsidiary focused on HIV. He has led businesses in the United States, Europe, and Japan, successfully launching and growing a range of innovative products, including therapies for orphan diseases. Dr. Dube has also managed commercial, operations, market access, medical, and business development functions.

Prior to ViiV, Dube worked at GSK for more than 18 years, in roles including leading the U.S. Oncology and Global Respiratory businesses. Dube’s responsibilities at GSK spanned critical areas including sales, marketing, market access, medical affairs, compliance, alliance management, and supply chain. He holds a Ph.D. and MA in Psychology from Cornell University and received his B.S. in Biopsychology from Santa Clara University.

“I am honored to succeed Steve as Retrophin’s next CEO and to lead an organization that plays such a critical role in patients’ lives,” said Dr. Dube. “I admire how Steve and the team at Retrophin have advanced the organization and developed a strong late-stage pipeline that has the potential to meet several unmet patient needs. I look forward to working with the Retrophin leadership and all of the dedicated team members to build upon the Company’s strong foundation and deliver life-changing therapies to people living with rare disease.”

January 3, 2018
Photo: Eric Dube, CEO of Retrophin